# Reducing a major cost burden of therapeutic cell manufacturing by selectivelyremoving toxic culture byproducts to allow recycling of media

> **NIH NIH R41** · OSSIUM HEALTH, INC. · 2021 · $224,453

## Abstract

ABSTRACT:
 The tremendous cost of cell-based therapies manufacturing is the significant threat to the success of
cell/gene therapy treatments. The cell culture medium alone can contribute to around 30-40% of the Cost of
Goods (COGs). This is because, the current cell culture methods require frequent and complete media
replacement in order to remove toxic metabolites from culture. This practice of completely replacing the medium
with fresh medium adds significant expense and contributes to unnecessary waste. Restoring nutrient, osmotic,
and pH balance need not require replacement of the entire culture medium volume. At production scale, some
version of medium recycling will be required to reduce waste and overall cost of manufacturing. The aim of the
current study is to develop a cost-effective media filtration system using coconut-shell derived activated carbons
(CS-AC) that can selectively remove two important toxic metabolites such as lactic acid and ammonium from
cell culture medium. With such filtration system, metabolic waste products can selectively be removed, non-
metabolized components like buffers, and growth factors can be retained, and the depleted nutrients like sugars
and amino acids can be replenished as they are consumed by the cells. Determining the level of recycling that
is achievable by this filtration technology for each component of the culture medium requires a significantly more
complex analysis informed by empirical data from spent medium analysis.
 The ultimate goal of this study is to utilize this filtration technology and develop a commercial grade
single-use filtration device by embedding the AC into cellulose matrix or neutral-grade resins. The application of
the new filtration device to remove toxic metabolites from spent culture medium will transform the current
approaches being investigated for COG reduction during cell based therapeutic manufacturing. Such a filtration
system holds a great promise for affordable cell/gene therapy treatment possibilities, and is expected to have a
strong economical impact on clinical medicine.

## Key facts

- **NIH application ID:** 10325616
- **Project number:** 1R41GM140787-01A1
- **Recipient organization:** OSSIUM HEALTH, INC.
- **Principal Investigator:** Emily Hopewell
- **Activity code:** R41 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $224,453
- **Award type:** 1
- **Project period:** 2021-09-20 → 2023-07-19

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10325616

## Citation

> US National Institutes of Health, RePORTER application 10325616, Reducing a major cost burden of therapeutic cell manufacturing by selectivelyremoving toxic culture byproducts to allow recycling of media (1R41GM140787-01A1). Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/grant/nih/10325616. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*